vs
FONAR CORP（FONR）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是FONAR CORP的6.3倍（$160.8M vs $25.5M）。TransMedics Group, Inc.净利率更高（65.6% vs 8.0%，领先57.5%）。TransMedics Group, Inc.同比增速更快（32.2% vs 2.4%）。TransMedics Group, Inc.自由现金流更多（$19.0M vs $-227.0K）。过去两年TransMedics Group, Inc.的营收复合增速更高（28.8% vs -0.3%）
FONAR是一家专业医疗技术企业，专注于设计、制造及销售包括立式、开放式在内的创新磁共振成像（MRI）设备，主要服务美国的医院、影像诊断中心及医疗机构，为临床诊断提供高精度扫描解决方案。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
FONR vs TMDX — 直观对比
营收规模更大
TMDX
是对方的6.3倍
$25.5M
营收增速更快
TMDX
高出29.8%
2.4%
净利率更高
TMDX
高出57.5%
8.0%
自由现金流更多
TMDX
多$19.2M
$-227.0K
两年增速更快
TMDX
近两年复合增速
-0.3%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $25.5M | $160.8M |
| 净利润 | $2.1M | $105.4M |
| 毛利率 | — | 58.1% |
| 营业利润率 | 13.5% | 13.2% |
| 净利率 | 8.0% | 65.6% |
| 营收同比 | 2.4% | 32.2% |
| 净利润同比 | 4.7% | 1436.9% |
| 每股收益（稀释后） | — | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FONRTMDX
| Q4 25 | $25.5M | $160.8M | ||
| Q3 25 | $26.0M | $143.8M | ||
| Q2 25 | $27.3M | $157.4M | ||
| Q1 25 | $27.2M | $143.5M | ||
| Q4 24 | $24.9M | $121.6M | ||
| Q3 24 | $25.0M | $108.8M | ||
| Q2 24 | $25.9M | $114.3M | ||
| Q1 24 | $25.7M | $96.8M |
净利润FONRTMDX
| Q4 25 | $2.1M | $105.4M | ||
| Q3 25 | $2.3M | $24.3M | ||
| Q2 25 | $729.3K | $34.9M | ||
| Q1 25 | $2.5M | $25.7M | ||
| Q4 24 | $2.0M | $6.9M | ||
| Q3 24 | $3.1M | $4.2M | ||
| Q2 24 | $830.4K | $12.2M | ||
| Q1 24 | $1.9M | $12.2M |
毛利率FONRTMDX
| Q4 25 | — | 58.1% | ||
| Q3 25 | — | 58.8% | ||
| Q2 25 | — | 61.4% | ||
| Q1 25 | — | 61.5% | ||
| Q4 24 | — | 59.2% | ||
| Q3 24 | — | 55.9% | ||
| Q2 24 | — | 60.6% | ||
| Q1 24 | — | 61.9% |
营业利润率FONRTMDX
| Q4 25 | 13.5% | 13.2% | ||
| Q3 25 | 14.1% | 16.2% | ||
| Q2 25 | 5.3% | 23.2% | ||
| Q1 25 | 15.2% | 19.1% | ||
| Q4 24 | 11.9% | 7.1% | ||
| Q3 24 | 21.0% | 3.6% | ||
| Q2 24 | 7.4% | 10.9% | ||
| Q1 24 | 16.8% | 12.8% |
净利率FONRTMDX
| Q4 25 | 8.0% | 65.6% | ||
| Q3 25 | 8.7% | 16.9% | ||
| Q2 25 | 2.7% | 22.2% | ||
| Q1 25 | 9.2% | 17.9% | ||
| Q4 24 | 7.9% | 5.6% | ||
| Q3 24 | 12.6% | 3.9% | ||
| Q2 24 | 3.2% | 10.7% | ||
| Q1 24 | 7.3% | 12.6% |
每股收益（稀释后）FONRTMDX
| Q4 25 | — | $2.59 | ||
| Q3 25 | — | $0.66 | ||
| Q2 25 | — | $0.92 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | — | $0.12 | ||
| Q2 24 | — | $0.35 | ||
| Q1 24 | — | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $121.0K | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.9M | $473.1M |
| 总资产 | $217.2M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FONRTMDX
| Q4 25 | $121.0K | — | ||
| Q3 25 | $122.0K | — | ||
| Q2 25 | $56.5M | — | ||
| Q1 25 | $123.0K | — | ||
| Q4 24 | $121.0K | — | ||
| Q3 24 | $136.0K | $330.1M | ||
| Q2 24 | $56.5M | $362.8M | ||
| Q1 24 | $134.0K | $350.2M |
总债务FONRTMDX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $66.9K | — | ||
| Q1 24 | — | — |
股东权益FONRTMDX
| Q4 25 | $176.9M | $473.1M | ||
| Q3 25 | $174.9M | $355.2M | ||
| Q2 25 | $172.6M | $318.1M | ||
| Q1 25 | $171.9M | $266.3M | ||
| Q4 24 | $169.8M | $228.6M | ||
| Q3 24 | $168.7M | $209.9M | ||
| Q2 24 | $166.0M | $189.9M | ||
| Q1 24 | $165.8M | $159.5M |
总资产FONRTMDX
| Q4 25 | $217.2M | $1.1B | ||
| Q3 25 | $218.4M | $946.0M | ||
| Q2 25 | $216.9M | $890.5M | ||
| Q1 25 | $214.9M | $837.5M | ||
| Q4 24 | $208.0M | $804.1M | ||
| Q3 24 | $212.3M | $785.6M | ||
| Q2 24 | $214.2M | $758.6M | ||
| Q1 24 | $209.6M | $723.8M |
负债/权益比FONRTMDX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $171.0K | $34.5M |
| 自由现金流经营现金流 - 资本支出 | $-227.0K | $19.0M |
| 自由现金流率自由现金流/营收 | -0.9% | 11.8% |
| 资本支出强度资本支出/营收 | 1.6% | 9.7% |
| 现金转化率经营现金流/净利润 | 0.08× | 0.33× |
| 过去12个月自由现金流最近4个季度 | $5.7M | $133.6M |
8季度趋势，按日历期对齐
经营现金流FONRTMDX
| Q4 25 | $171.0K | $34.5M | ||
| Q3 25 | $1.7M | $69.6M | ||
| Q2 25 | $4.2M | $91.6M | ||
| Q1 25 | $3.1M | $-2.9M | ||
| Q4 24 | $2.2M | $19.7M | ||
| Q3 24 | $1.7M | $6.9M | ||
| Q2 24 | $4.6M | $25.7M | ||
| Q1 24 | $2.8M | $-3.4M |
自由现金流FONRTMDX
| Q4 25 | $-227.0K | $19.0M | ||
| Q3 25 | $-177.0K | $61.9M | ||
| Q2 25 | $3.6M | $82.5M | ||
| Q1 25 | $2.6M | $-29.9M | ||
| Q4 24 | $1.5M | $6.1M | ||
| Q3 24 | $-148.0K | $-41.3M | ||
| Q2 24 | $4.2M | $2.0M | ||
| Q1 24 | $2.6M | $-47.6M |
自由现金流率FONRTMDX
| Q4 25 | -0.9% | 11.8% | ||
| Q3 25 | -0.7% | 43.1% | ||
| Q2 25 | 13.1% | 52.4% | ||
| Q1 25 | 9.4% | -20.8% | ||
| Q4 24 | 6.0% | 5.0% | ||
| Q3 24 | -0.6% | -38.0% | ||
| Q2 24 | 16.1% | 1.7% | ||
| Q1 24 | 10.2% | -49.2% |
资本支出强度FONRTMDX
| Q4 25 | 1.6% | 9.7% | ||
| Q3 25 | 7.2% | 5.3% | ||
| Q2 25 | 2.4% | 5.8% | ||
| Q1 25 | 2.2% | 18.8% | ||
| Q4 24 | 3.0% | 11.2% | ||
| Q3 24 | 7.2% | 44.3% | ||
| Q2 24 | 1.6% | 20.8% | ||
| Q1 24 | 0.7% | 45.6% |
现金转化率FONRTMDX
| Q4 25 | 0.08× | 0.33× | ||
| Q3 25 | 0.75× | 2.86× | ||
| Q2 25 | 5.79× | 2.62× | ||
| Q1 25 | 1.26× | -0.11× | ||
| Q4 24 | 1.14× | 2.87× | ||
| Q3 24 | 0.53× | 1.63× | ||
| Q2 24 | 5.54× | 2.11× | ||
| Q1 24 | 1.50× | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
